Early Developability Assessment For Antibody Based Therapeutics

As the biopharmaceutical industry increasingly shifts toward advanced multi-specific antibody formats and other complex biologics, the challenges associated with drug development have grown significantly. While these sophisticated molecular architectures offer enhanced therapeutic potential, they also introduce increased risks related to manufacturability, stability, potency, and immunosafety. To improve the likelihood of clinical and commercial success, these critical attributes must be evaluated as early as possible during the discovery phase. Early integration of developability assessments into molecular design enables potential liabilities to be identified and mitigated before candidate sequences are finalized, reducing downstream risk and accelerating progression through development.

To address these challenges, Lonza has developed a comprehensive toolbox approach designed to de-risk the development of multi-specific antibody therapeutics through a combination of in silico and in vitro technologies. The platform integrates high-throughput computational developability screening, optimized vector design, the proven and scalable GS Expression System®, and robust human immune cell assays to assess key product attributes at an early stage of development. This strategy enables rapid evaluation of titer, product quality, potency, manufacturability, and immunosafety, generating a stronger early-stage data package that supports more informed candidate selection and faster advancement into clinical development. By embedding these capabilities within a proactive de-risking framework, drug developers can improve decision-making, streamline development timelines, and gain a strategic advantage in the increasingly competitive landscape of multi-specific antibody therapeutics.

Key learning objectives include understanding the developability and immunosafety risks associated with multi-specific antibodies and complex biologic formats, learning how integrated in silico and in vitro screening approaches enable earlier risk mitigation and more informed lead selection, and recognizing how a toolbox-based strategy can accelerate development while strengthening early-stage decision-making.